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Key Points
- Representatives of the pharmaceutical industry call for a broader recognition of value
within the assessment and appraisal of innovative drugs
- Focus on value within the assessment and appraisal of drugs is jeopardized by financial
drives as the side of industry and at the side of the payers
- A well-considered value-framework, with attention for patient reported outcomes,
societal preferences and dynamic approach on the drug life cycle, needs to be
incorporated in assessment and appraisal at national and European level in order to
coordinate the views of different stakeholders and allow efficient resource allocation
This study presents industry perspectives on the challenges related to market access
of innovative drugs in general and oncology drugs in specific. Fifteen interviews were
conducted with representatives of pharmaceutical companies and industry associations.
Interviewees call for a broader recognition of value within the assessment and appraisal of
drugs. According to interviewees, focus on value is jeopardized by the lack of a common
value definition across Europe, poor availability and validity of value measures and
cost-saving measures such as external reference price setting and cost-effectiveness
analysis at the side of the payers. Centralized assessment of relative-effectiveness
at European level would provide a common value estimate across member states,
independent of financial drivers. Empirical evidence on PRO and societal preferences
is however essential in the development of a value definition. Furthermore, value-
based pricing would imply a dynamic approach where the price is differentiated across
indications and across the lifecycle of the drug, especially in fields such as oncology.
Financial drivers however also threat the application of value-based pricing at the side of
the industry, making value-based profitability a more appropriate term.
Keywords: drug development, market access, pricing and reimbursement, health technology assessment,
oncology, health economics, qualitative research, industry
INTRODUCTION
In the aftermath of the economic crisis of 2010, public spending to health care is recovering slightly
in line with the economic growth since 2013 (OECD, 2015). Spending to pharmaceuticals was cut
by the introduction of cost containment measures in many countries and the end of the patents
for some blockbuster drugs (OECD, 2015). In times of budgetary constraints, health authorities
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and payers still keep struggling with new innovations that offer
in their view too limited benefits at an unjustified high price. This
is even more important for disease areas as oncology, in which
high unmet needs remain. With more than 3 million new cases
and 1.7 million deaths each year, cancer remains the second most
important cause of death andmorbidity in Europe (WHO, 2014).
The oncology market is typically expanding by high cost drugs
that offer relatively limited benefits in terms of overall survival
(OS) or progression free survival (PFS) (Garattini and Bertele,
2002). Ipilimumab is one of the numerous examples of drugs
that has recently been highly criticized as an over expensive drug
since it was launched in UK at a price of £75,000 for a four dose
treatment course, yielding 3.7 months in median overall survival
in the phase 3 trial (NICE, 2012). Pharmaceutical companies
are put under pressure and blamed for setting unsustainably
high prices that threaten the accessibility of health care for
patients (Experts in Chronic Myeloid Leukemia, 2013). While
an upward trend in both the launch price of oncology drugs
as well as the price per unit of health gain indeed raises
questions about the future sustainability and accessibility of
public health care systems (Garattini and Bertele, 2002; Howard
et al., 2015), a decline in economic return for pharmaceutical
companies possibly threatens future innovation (Berndt et al.,
2015). The current pipeline is however well-filled with oncology
agents, promising evolutions toward individualized therapies,
immuno-oncology, and combination treatment schemes and
thus predicting more hurdles to overcome (IMS Institute for
healthcare informatics, 2015).
Marketing authorization is currently centralized at European
level for most drugs, including oncology drugs, and involves
a first step in assessment of the drugs’ safety, quality, and
efficacy irrespective of financial consequences or relative benefit
compared to alternatives. Drug appraisal, comprising the value of
the drug in relation to its competitors, is exclusively performed
at the national level of the member states in the context of
price setting and reimbursement decisions. Previous research
already showed a variety of instruments for price setting and
reimbursement of oncology drugs across European member
states, leading to heterogeneity across and within countries, and
poor transparency toward all stakeholders involved (McCabe
et al., 2009; Pauwels et al., 2014). Efficient allocation of the scarce
resources and sustainable development and access to innovative
drugs can only be obtained when stakeholders coordinate their
individual views as much as possible. The aim of this study
is to reveal the perspective of the pharmaceutical industry on
development and market access of innovative drugs in general
and oncology drugs in particular, and discuss their proposals for
future improvement.
METHODS
Semi-structured interviews were conducted with representatives
of the pharmaceutical industry between August and November
2015. Interviewees were invited through e-mail and telephone
based on purposive sampling. Companies with oncology drugs
in their current or past product portfolio were selected.
Additionally, two industry associations were included.
Interviewees affiliated to these companies or associations
were selected based on their knowledge and experience
related to market access strategies, including marketing
authorization, price setting, and reimbursement of (oncology)
drugs. After searching the literature for evidence about industry
perspectives on market access of drugs in general, an interview
guideline was designed by selecting eight relevant statements
from the literature (Table 1). The statements were discussed with
the interviewees during face-to-face interviews or by telephone,
dependent on their availability and preferences. Notes were
taken during the interview and in case of permission of the
interviewee, the interview was audio-recorded and ad verbatim
transcribed. The grounded theory approach was applied to
analyze the interviews using the qualitative data analysis software
package Nvivo R©. All transcripts were anonymized. Interviews
were repeated until data saturation. All interviewees received the
results section for final approval, while the remaining manuscript
was written independently.
RESULTS
Fifteen interviews were conducted, involving 13 pharmaceutical
companies and two pharmaceutical industry association. Two
of the fifteen interviews were conducted by telephone instead
of face-to-face. Fourteen of the fifteen interviews were audio
recorded.
Research and Development
It was previously suggested in literature that companies
sometimes focus on research hypothesis instead of unmet
medical or social needs (Drummond et al., 2013). Interviewees
show divergent opinions on the role of medical and social need
in the orientation of research and development of innovative
drugs. While some interviewees agree that social or medical need
has no impact or only becomes important at a later stage of
development, others indicate that social and medical need is
increasingly driving drug development.
“Patients are put in the first place, second we have to create trust
amongst our payers, amongst our patients and physicians, and
then, in the end the business will follow and the money will come...
we have a commercial organization and in the end it is about
revenues, that is correct, but we put patients in the first place.” (I1)
For some interviewees it is not completely clear what the health
authorities’ needs and priorities are.
“We have no clear guidance on the unmet needs that needs to be
worked upon. Where are the priorities? They have not been put
forward. So how can we address those unmet needs if we don’t know
what they are for the authorities?” (I2)
According to other interviewees, needs are perceived in function
of willingness to pay related to pricing and reimbursement.
“A drug that does not bring added value will have lot of difficulties
to get reimbursed. Today, there are already a lot of incentives
to orient investment and research in function of a need.” (I3)
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TABLE 1 | Statements from the literature for semi-structured interview guideline.
“Manufacturers sometimes set research priorities on the basis of the pursuit of a research hypothesis, as opposed to developing new technologies that meet unmet
social need” (Drummond et al., 2013)
“Resources for development of new technologies can be used much more effectively if industry and HTA agencies were to collaborate at an early stage in the
development process” (Jöhnsson, 2015)
“The main actors in the health care sector have different perspectives on the value added by health technologies” (Drummond et al., 2013)
“Manufacturers feel that the restrictions on the use and price of health technologies resulting from HTAs limits their sales potential and ultimately the profits from which
future research has to be funded” (Drummond et al., 2013)
“It has been discussed if the QALY fully captures the benefits of new cancer drugs. The higher cost per QALY criteria for oncology drugs may reflect a view that there may
be an additional benefit or value of treatment that should be considered” (Jönsson, 2013)
“The question how to define justifiable prices for oncology drugs needs to be addressed. Currently, prices are often set in relation to international standards and
investments of manufacturers” (Fibig, 2013)
“Value-based pricing is likely to give manufacturers an incentive to more closely align their R&D with social objectives” (Fibig, 2013)
“If all elements of value are considered and taken into account in decision making, there is a risk that higher prices will be the result” (Fibig, 2013)
“I don’t think that we would develop a technology that meets a need
if nobody is going to pay for that need. Because there is no market,
no opportunity for companies” (I4)
Some interviewees do not believe that willingness to pay can steer
research and development into a certain direction.
“It would be possible to indicate the areas where there is a need,
where it would be interesting to do research...but I don’t believe that
you can guide research...you need companies that do their research,
they can come with a proposal, and then the society has the right to
say it is not relevant enough, we don’t pay for it.” (I5)
Marketing Authorization
Currently, national legislation and practice in European member
states concerning price setting and reimbursement of drugs leads
to a heterogeneity across Europe. Interviewees are in favor of a
centralized assessment of the relative benefit at European level
within the process of marketing authorization. This would make
the focus for companies more clear as it can provide a common
basis for assessment and appraisal of drugs across European
member states.
“The assessment of relative efficacy and effectiveness based on
solid science presents a set of core similarities across countries. It
is therefore reasonable that greater collaboration would enhance
efficiency and predictability for all stakeholders involved.” (I6)
Price Setting
Interviewees however hold the opinion that as long as the
economic system is different for each country, the appraisal of
pharmaceuticals needs to remain a national responsibility, and
price must depend on the national budget and priorities.
“I don’t believe that price setting in Europe needs to be
homogenous....you need to differentiate across countries.... But
currently it is transforming toward a national competence that is
more embedded in Europe, and this is a good thing.” (I5)
Interviewees emphasize that prices should however not just allow
to cover costs made in the past but more importantly, needs to
ensure investments in the future pipeline.
“First of all, you want to make a difference, second, you want to
make money. Not just because you love to earn money, but because
you would like to keep things going. We want to develop, we want
to innovate. Of course you need to please shareholders and draw
dividends and make profits but most important, you want to keep
going the R&D.” (I7)
Companies further fear they cannot meet the expectation
of the payers. According to the interviewees, payers only
show willingness to pay for breakthrough innovation, while
interviewees are convinced that a step by step approach will lead
to tremendous benefits at the long-term.
“I mean if companies would be able to just produce what payers are
expecting, and just breakthrough...I think they would do it. If they
don’t, it is just because it doesn’t work that way.” (I4)
It is indicated by interviewees that the focus on medical needs
provokes a shift from pharmaceuticals for primary care to
specialized medicines where the volume of sales is lower and
therefore price needs to be higher to recoup the costs.
“The more specific you go, the less patients there are and therefore,
the cost should sometimes be higher to recoup the investments.” (I8)
A number of countries currently applies external reference
pricing (ERP) in order to set prices based on the price in a
basket of other countries. This can lead toward harmonization
of price levels. Furthermore, a price decrease in one particular
country can have a tremendous effect on price levels in the basket
of reference countries, and interviewees confirm that this can
motivate pharmaceutical companies to keep list prices high.
“Also you have countries who use ERP, who create a system where
prices are kept as high as possible by companies. I think that is an
Frontiers in Pharmacology | www.frontiersin.org 3 June 2016 | Volume 7 | Article 144
Pauwels et al. The Relevance for Oncology Drugs
aspect of the situation that explains why oncology drug prices are
kept as high as possible, and cannot be defined in just one way, or
justified in just one way.” (I9)
It was emphasized that the inherent value of the drug is neglected
within the system of ERP.
“The problem that we see today is that a lot of countries have this
health technology assessment (HTA), but at the same time there
is this ERP. What is the aim of having these data or having this
discussion around which premium is appropriate when in the end
you say I am not willing to pay more than my neighbor?” (I4)
Also taking into account cost-structure within price setting will
not provide the right incentives according to the industry.
“Think in terms of incentives. If they pay your R&D costs, they say it
doesn’t matter what you develop, they will pay it anyway. The only
right incentive is to pay a fair price for products they need, and that
is value-based pricing. The government needs to say develop value
and we will pay for it.” (I7)
Clinical Value
Companies value a drug based on the clinical, economic,
and societal value. Interviewees indicate that the full value
of the product is currently not sufficiently captured during
the assessment and appraisal of drugs. At the clinical level,
interviewees doubt whether OS and PFS cover the long-term
benefits of treatments based on new mechanisms of action such
as present in immuno-oncology.
“The clinical benefit scale captures todays clinical value. We look at
the curve of PFS or OS, and basically we know that until 5 years
value can be captured in clinical trial setting, but what can’t be
captured is the area after the curve that looks at the longer quality
of survival. And this is not captured everywhere, and I suppose it is
normal because these things that are coming to the market are new.
There is work to be done to develop value mechanisms beyond the
clinical trial setting, tools that allow to capture broader value. And
really today what is being used is the median OS, or PFS. We think
that this should be broader to really capture what is the benefit.”
(I10)
Further, it is questioned by interviewees whether OS, PFS, and
quality of life cover most relevant outcomes according to patients
and physicians.
“The focus is recently very much on OS and quality of life but...I
think there are other things that can define the value of the drug.
How many patients can you treat with your drug? Is it a drug
with a different mode of action? What can this bring to the
patient and the physician? Is it interesting to have one more drug,
without necessarily prolonging survival? Is it good to have one extra
therapeutic option?” (I9)
Interviewees call for standardized, validated and recognized
measures for patient reported outcomes (PRO).
“How do you measure quality of life or PRO in a way that gives
you data that are recognized as valid?... There is no guidance or
commonly agreed framework on how we should do it.” (I10)
Societal Value
At the economic and societal level, interviewees feel that the
broader economic and societal value of a product, resulting from
savings at the long term, such as recessed hospitalizations and
absence from work, is often ignored by decision makers.
“Very often many countries don’t include societal perspectives. So
what about the treatment costs after cure? Very often you have to
model or calculate costs during the disease period, but if you cure,
the patients survive, what about the additional costs or savings after
surviving?” (I11)
Cost-Benefit Analysis
Cost-effectiveness analysis is introduced in a large number of
European countries in order to evaluate the cost-benefit ratio
of a drug in terms of an incremental cost-effectiveness ratio
(ICER), expressed as cost per quality adjusted life year (QALY).
This was recognized by interviewees as an appropriate tool to
compare the costs and benefits of different treatments with
each other but several remarks on the system where provided.
Several interviewees argued that considering an ICER within
price setting and reimbursement evaluations does not provide
appropriate incentives to the pharmaceutical industry. According
to the interviewees, the ICER motivates to develop in an area
where existing treatments are expensive, because you can add up
the price of the new technology to the existing price, resulting
in a lower ICER compared to the situation where there is
no (expensive) alternative treatment. Due to methodological
requirements, costs per QALY will always be too high in domains
where effectiveness is low and patient populations are small.
“In the field of unmet needs, you will be punished by the QALY
system because you have no cost-reference. By considering cost per
QALY, they say do not develop in an area where prices are low, do
not develop in an area where there are no big gains in effectiveness
expected and do not in an area where patient populations are
small.” (I7)
Furthermore, disease specific outcome that are of high relevance
for the patient are often not captured in QALY measures as these
are mainly based on health outcomes measured with EQ5D, a
standardized, five dimension scale developed by Euroqol.
“EQ5D does not capture everything, like hair loss is not captured,
so hair loss has no influence on the QALY. Which is crazy because
I can imagine that hair loss would have an impact on quality of
life.” (I3)
Implications for Oncology Drugs
Interviewees urge on a broader consideration of value through
the lifecycle of the product especially when drugs are initially
only used in late stage diseases, such as is often the case for
oncology drugs. This is due to ethical considerations, where one
Frontiers in Pharmacology | www.frontiersin.org 4 June 2016 | Volume 7 | Article 144
Pauwels et al. The Relevance for Oncology Drugs
tries to address the highest need and minimize potential risks for
patients. This makes it hard to prove value in the initial stage of
drug assessment and appraisal. Benefits will anyhow be larger at
a later stage of market access when the indication has broadened.
“Once an oncology medicine is more established, it can be used in
an adjuvant curative setting, as in patients with better prognosis,
before tumors have spread. Measured outcome, by definition for
such patients are often better than patients whose cancer is more
advanced. Often, prices that were too high at initial assessment, can
turn out cost-effective by the time the medicine is in an adjuvant or
broader use.” (I6)
Additionally, recognition of value can mean restriction of the
drug toward the most valuable indication.
“Personally I believe you should use the drugs where they are most
appropriate. You should use them where they deliver the highest
value. Where they deliver the highest value you can justify better
your price than when they are used in an inappropriate way.” (I12)
Alternatively, if payers recognize value and are willing to apply
value-based pricing, they would be ready to apply indication
specific pricing, as the value for oncology products can definitely
differ between indications.
“Now we have average prices per milligram. And you can have a
drug in breast cancer, colorectal cancer, and adjuvant breast cancer
and today this drug has the same price per milligram in all these
indications. If we are in a society that is willing to pay for value, then
the pricing model should allow for different prices per indication, as
the value of the drug might be very different. This could make the
discussion more acceptable for all stakeholders.” (I3)
Belgium
Several issues related to the Belgian system for price setting
and reimbursement of drugs were mentioned based on the
experience of the interviewees with relation to price setting
and reimbursement files concluded in Belgium in the past. In
the Belgian law, therapeutic value is defined in function of
efficacy, effectiveness, safety, applicability, and convenience for
use. Therapeutic value is considered following the application
for reimbursement, together with the price of the drug, the
therapeutic and social need, and budget impact and cost-benefit
ratio1. Interviewees are favorable to the law, but are critical of
the application in practice. They have the impression that at
the Belgian level, budgetary control currently overrules value
assessment.
“I think the law goes very broad and specifies the five criteria that
they use to define the added value of a drug. But in the end you
always see that it boils down to the cost of your drug compared to
the cost of the other ones. Adding quality of life, adding efficacy,
adding a better safety for your drugs, and especially quality of life
1Koninklijk Besluit tot Vaststelling van de Procedures, Termijnen en Voorwaarden
Inzake de Tegemoetkoming van de Verplichte Verzekering voor Geneeskundige
Verzorging en Uitkeringen in de Kosten van Farmaceutische Specialiteiten.
(2001). Available online at: http://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?
language=nl&la=N&table_name=wet&cn=2001122138 (Accessed Aug 25, 2012).
and safety aspects... usually they are not valued that high by the
authorities.” (I1)
Cost-effectiveness analysis is mandatory for drug that claim
added therapeutic value. Some interviewees perceive it only as
an entry ticket to the procedure which is not further taken
into account in the evaluation for reimbursement, since budget
impact takes the lead. Other interviewees mention that even
when your budget impact is relatively low, the ICER will be put
forward as an issue.
“If you are not cost-effective you don’t get reimbursement, but if you
are cost-effective, the budget can be too high. Cost per QALY must
be zero in Belgium before you can get reimbursement.” (I1)
Interviewees call for a better recognition of the patient
perspective. In the current system, health insurance funds have
the task to represent the patients, but at the same time they
are responsible for the public health budget, which results in a
dual role with inherent conflicts. This further strengthens budget
impact as a deciding factor for reimbursement.
“Health insurance funds took the responsibility to defend the
patient. They probably did that in good faith, but know they are
payer as well as patient representative. That is a dual role, which is
not easy.” (I5)
Companies show incomprehension toward the Belgian practice
in which reimbursement for an additional indication is coupled
with a price decrease. When an additional indication is approved
for a drug that was already reimbursed, the company needs to
compensate one third of the additional budget impact related
to the new indication. This gives the impression toward the
companies that the added value of this new indication is not taken
into account.
“The rule in Belgium in very special. When you can show the budget
impact with the new indication compared to budget impact that
was existing without a new indication, one third of the increase in
the budget should be taken by the company, meaning that you have
to decrease the price of the product by X percent. ... But maybe you
can show really a therapeutic added value for the new indication,
this will not be taken into account.” (I13)
Interviewees indicate that there is no fixed period of exclusivity
anymore where companies can recoup their costs and this
introduces new financial uncertainties to the companies.
Companies will anticipate on price pressure and price erosions,
leading to higher prices at initial price setting.
DISCUSSION
This study presents industry perspectives on the challenges
related to market access of innovative drugs in general and
oncology drugs in specific. Industry calls for a broader
recognition of value within the assessment and appraisal of
drugs. Pricing in function of value has the potential to stimulate
valuable innovation since industry is eager to orient research
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and development of drugs in function of willingness to pay. The
lack of a common value definition across European member
states, poor availability, and validity of value measures, as well
as financial responsibilities at the side of both industry and payer,
however threat the application of value-based pricing.
The pharmaceutical landscape is currently changing. While
in the early 90’s massive entities were set up to profit from the
economies of scale, companies currently focus on one particular
area of strength (Gautam and Pan, 2015). This goes along with
a move from drugs for primary care toward specialty drugs and
biologicals for unmet needs (Gautam and Pan, 2015).While some
companies hold on the principle of a supply driven market where
payers need to deal with what industry brings on, a transition
toward a demand driven market was observed in this study.
Companies show willingness to orient their investments to areas
of unmet needs, on the condition that the priorities are clearly
defined and benefits in areas of unmet need will be rewarded.
Companies have to tailor drug applications to the individual
market requirements in European member states, evoking
frustrations at the side of the company when objective measures,
even those assessed at European level such as efficiency and side
effects, are not treated the same way across member states. In
the first step of drug assessment, regulators however only focus
on the balance between benefits and risks to grant marketing
authorization. Clinical superiority was only defined at European
level in the context of EU orphan drug legislation in 2000. In
2008, the High Level Pharmaceutical Forum of the European
Commission published core principles on clinical superiority
including a definition on relative efficacy (RE) (Eichler et al.,
2010). First pilot projects of The European Network for Health
Technology Assessment (EUnetHTA), established in 2009 in
order to work toward more effective use of resources in the HTA
process, strived for a common HTA assessment report across
European member states, presenting the core HTA information
(EUnetHTA, 2015). An assessment of the external validity of
national assessments of RE however resulted in a pessimistic view
on potential harmonization (EUnetHTA, 2015). Although there
appears to be a commonality between the use of RE at national
level, the way that study design, outcomes and comparators
were evaluated and accepted differs (EUnetHTA, 2015). Early
dialogue can aid understanding of possible differences and will
allow companies to consider the product development fit for
regulatory purposes. Therefore, the Shaping Early Dialogue
(SEED) consortium was set up in 2014 under supervision of
Haute Autorité de Santé (HAS) in order to include 14 partners
within 10 early dialogues between 2014 and 2015. Centralized
assessment of RE is clearly not likely to be quickly achieved, but
there is a growing belief from industry as well as regulators that
EU assessment of RE can strength the EUmarket and is expected
to trigger allocation of research and development resources away
from me-too drugs toward drug development programs that aim
superiority claims (Eichler et al., 2010; Bergmann et al., 2015).
Centralized assessment of RE based on transparent grounds can
enable focused clinical trial design with generation of relevant
data (Bergmann et al., 2015). Costs will be lower and quality
will be improved at the benefit of both industry and public
health systems, on the condition that the assessment of RE is
recognized and shared across MS. Standards for clinical trials will
therefore raise when evidence needs to be reliable and applicable
to all MS. While industry believes a centralized assessment of
RE can harmonize and strengthen value consideration within the
assessment by national health authorities, some authors doubt
whether this would lead to enhanced access to cancer medicines
as drug appraisal, related to health care costs, remains to be
managed at national or local level (Bergmann et al., 2015).
At the side of the payers it is debated whether prices of drugs
are still proportionally related to their benefits (Howard et al.,
2015; IMS Institute for healthcare informatics, 2015). At the
same time, pharmaceutical companies doubt whether current
assessment and appraisal procedures capture the full value of
drugs. Administrative pricing procedures such as ERP anyhow
neglect the intrinsic value of the drug and although the number
of countries that solely relies on this pricing method is limited,
the influence on industry strategies and consequently medicine
prices needs to be emphasized (Leopold et al., 2012a,b). ERP,
together with the fact that parallel trade is allowed within the EU
single market, can urge companies to artificially keep up the list
price, which does not reflect confidential discounts and rebates.
In countries such as Belgium, this can exemplify conflicting
interest when the main focus of payers is on the budget, while
the Belgian list price is used as a reference in a large number of
other countries applying ERP. Industry perspectives indicate that
the Belgian policy and practice fosters price setting away from the
inherent drug value, as companies intend to anticipate on price
erosions, budgetary pressures and an impact on the price in other
countries due to ERP. A comparison between value-based pricing
and EPR, conducted in the lap of the European Commission, was
anyhow in favor of value-based pricing since EPR does not aim
to reward (future) innovation (Kanavos et al., 2010). According
to the EU commissions report, development of valuable drugs
can only be motivated when assessments and appraisal consider
a societal perspective in determination of costs and benefits
associated with a new technology (Kanavos et al., 2010). Evidence
about the societal worth of a broader benefit consideration is
increasing. A study in 4118 citizens of Great Britain suggested a
significant value for wider societal benefits (Linley and Hughes,
2012). Also a population study conducted in Belgium showed
that the effect of innovations on current expenditures is valuable
according to society (Cleemput et al., 2014). While siloed
funding is applied among European countries, the Swedish
Dental and Pharmaceutical Benefits Agency (TLV) is one of
the sole exemptions where pricing and reimbursement decisions
focus on value from the societal perspective instead of the
health care perspective only (Kanavos et al., 2010). According to
TLV guidelines, this means that all relevant costs and revenues
irrespective of the payee should be considered, including cost
of production loss and cost of increased survival as well as
benefits to both caregivers and patients (TLV, 2003). Prices in
Sweden are however among the highest in Europe and adoption
of the societal perspective considerably increases the information
requirements, so attention for accessibility in terms of time and
price is an asset (Kanavos et al., 2010; Vogler et al., 2015).
With regard to clinical benefits, research already suggested that
societal valuation of quality of life is overruling the valuation
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of life expectancy when considering both the initial health
state of the patients as well as treatment effects (Bryan et al.,
2002; Schwappach, 2003). Several stakeholders currently call
for a broader inclusion of PRO, referring to multi-dimensional
measures of symptoms, quality of life, health status, treatment
adherence, and treatment satisfaction. Demographic evolutions
toward an aging population and more chronic diseases provide
a context in which the relevance of outcomes related to the
wellbeing of the patient, such as of quality of life in the broad
sense is growing. By the end of 2014, a reflection paper discussing
the use of PRO in oncology was added to the scientific guidelines
for quality, safety, and efficacy requirements prepared by the
European Medicines Agency’s (EMA) Committee for Human
Medical Products (CHMP) (EMA, 2014). In this reflection paper,
the benefit of capturing personal and social context of the
disease and treatment experience in addition to objective clinical
measures such as OS and PFS was set against its challenges in
setting the degree of clinically relevant differences, difficulties
in sensitivity, and problems with feasibility in longitudinal
studies (EMA, 2014). Results in lung cancer previously showed
that similar outcomes where shown for PFS than for time to
significant deterioration in tumor related responses as measured
by PRO, questioning the added value of PRO (EMA, 2014).
Validated tools to measure PRO, also including Health Related
Quality of Life (HRQoL) measures are scarce. Weighting systems
to link disease specific quality of life outcomes to utility scores
are even lacking; challenging their use in cost-effectiveness
analysis. Generic health classification systems such as EQ5D
remain the single valid tool for QALY weighting, often based
on population preferences since also at this level disease specific
patient preferences are lacking.
Pricing in terms of clinical-effectiveness as well as cost-
effectiveness, sets the costs and benefits of a new treatment
against those of the existing alternatives and it was argued by
Howard et al. that setting prices of new drugs based on prices
of existing therapies is also against intrinsic value consideration,
consistent with models for reference pricing (Howard et al.,
2015). The benefit of the new drug can add up to the price
of existing treatments, providing incentives for development
in areas of highly priced existing therapies. Cost-effectiveness
analysis in oncology is anyhow to the prejudice of industry
since it is often applied immediately after launch, considering
advanced, or palliative stages of the disease. The End-of-Life
guidance was introduced in UK to adjust the cost-effectiveness
threshold for late stage treatments. Although society attaches
higher value to treatments for more severe disease, treatments
for palliative diseases as such, are not valued higher than
treatments for early stages of diseases (Linley and Hughes, 2012).
In the Netherlands, the thresholds are applied in a flexible way,
adjusting these to severity of disease (Pauwels et al., 2014).
The evolutions in drugs development are however likely to
further threaten the applicability of cost-effectiveness analysis
as the relevance is somewhat questioned within small patient
populations and combination therapies. Because the price per
milligram is fixed across indications while value can differ, the
actual cost-effectiveness also varies across indications. Oncology
drugs are characterized by multiple indications with more than
50% of major cancer medicines marketed in 2014 were for
multiple indications (IMS Institute for healthcare informatics,
2015; Mestre-Ferrandiz et al., 2015). Setting a price based on the
indication shortly after launch can influence patient access during
the life cycle of the drug. If the single price is based on higher
value indications, the price might be higher than what is optimal
for subsequent indications, leading to restricted access (Mestre-
Ferrandiz et al., 2015). If the price is initially set for lower valued
indications, which will often be the case for oncology drugs,
this might discourage companies to further develop valuable
indications (Mestre-Ferrandiz et al., 2015). As value changes
over the life cycle of a drug, value-based pricing challenges a
dynamic life cycle approach where price discrimination across
indications is allowed. Managed entry agreements allow to set
confidential contributions based on performance of the drug,
even beyond clinical trial setting, promising a leading role for
managed entry agreements for oncology drugs in the future. It
is however doubted that industry is ready to set the price fully
in relation to value as this will not lead to sufficient return in
particular situations such as small indications, making value-
based profitability a more appropriate concept than value-based
pricing. Furthermore, besides a considerable responsibility in
sustaining the provision of and access to innovative drugs, the
financial responsibilities of health authorities toward the budget
cannot be neglected. It remains tricky how to define value and
link value with an acceptable price level for all stakeholders,
involving an acceptable profitability toward the industry and
reasonable budgetary impact toward the health authorities.
This study suffers of three main limitations. First, despite
the fact that interviews were repeated until data saturation, a
variety of opinions was observed across interviewees. The results
of this study aim to reflect these differing opinions. Second, the
experience of some of the interviewees was limited to the Belgian
situation, while the results are applied to the European situation
in general. Third, the experience of majority of the interviews
refers to innovative drugs in general and not solely to oncology
drugs, therefore results specific for oncology drugs are described
separately.
CONCLUSION
Value consideration is key, especially in expanding areas that face
expensive therapies such as oncology. On the one hand value
consideration can help to define priorities, pursue, and reward
development of valuable drugs at the benefit of industry. On
the other hand, a clear value definition can help to discriminate
between therapies that offer marginal or substantial benefits at
the side of the benefit of the payer. Focus on value is however
jeopardized by financial drivers both at the side of the industry
(return) and payers (budget). Centralized assessment of RE
can provide a common value estimate across member states,
independent of financial drivers. Given current demographic
and scientific evolutions, re-consideration of the concept of
value is however required and empirical evidence suggests that
developments of validatedmeasures for PRO and societal benefits
are appropriate. At the level of the member states, payers needs
to take account of contradictory incentives for industry that some
cost-saving measures such as ERP and cost-effectiveness analysis
can evoke.
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